Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
1 other identifier
interventional
N/A
1 country
33
Brief Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 12, 2002
CompletedFirst Posted
Study publicly available on registry
September 16, 2002
CompletedFebruary 6, 2006
February 1, 2006
September 12, 2002
February 2, 2006
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens.
You may not qualify if:
- Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment
- Clinically significant pulmonary dysfunction.
- Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment).
- Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
- History of autoimmune disease.
- History of positive serology for human immunodeficiency virus (HIV).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (33)
ACRC/Arizona Clinical Research Center, Inc.
Tucson, Arizona, 85712, United States
Hoag Cancer Center
Newport Beach, California, 92658, United States
UC Davis Cancer Center
Sacramento, California, 95817, United States
John Wayne Cancer Institute
Santa Monica, California, 90404, United States
Stanford University Medical Center
Stanford, California, 94305-5151, United States
California Cancer Medical Center
West Covina, California, 91790, United States
Georgetown University Medical Center, Lombardi Cancer Center
Washington D.C., District of Columbia, 20007, United States
Washington Cancer Institute
Washington D.C., District of Columbia, 20010, United States
Division of Hematology/Oncology, University of Miami School of Medicine
Miami, Florida, 333136, United States
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, 60611, United States
Rush Cancer Institute
Chicago, Illinois, 60612, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, 60068, United States
Cancer Care Center
Bloomington, Indiana, 47403, United States
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, 40207, United States
Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology
Shreveport, Louisiana, 71130, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, 64111, United States
Arch Medical Group, LLC
St Louis, Missouri, 63141, United States
Dartmouth-Hitchcock-Medical Center
Lebanon, New Hampshire, 03756, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
Our Lady of Mercy Medical Center, Comprehensive Cancer Center
The Bronx, New York, 10466, United States
East Carolina University School of Medicine/ Division of Hematology/Oncology
Greenville, North Carolina, 27858, United States
Roger Maris Health System
Fargo, North Dakota, 58122, United States
Gabrail Cancer Center
Canton, Ohio, 44718, United States
Oncology Hematology Care Inc.
Cincinnati, Ohio, 45242, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Hematology /Oncology Consultants Inc.
Columbus, Ohio, 43235, United States
Oregon Heath and Science University
Portland, Oregon, 97201, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Cancer Centers of the Carolinas
Greenville, South Carolina, 29615, United States
Germantown Cancer Center
Germantown, Tennessee, 38138, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Cancer Specialists of South Texas, P.A.
Corpus Christi, Texas, 78412, United States
Virginia Cancer Institute
Richmond, Virginia, 23230, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 12, 2002
First Posted
September 16, 2002
Last Updated
February 6, 2006
Record last verified: 2006-02